These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 27090900)
1. Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis. Qin G; Li X; Chen Z; Liao G; Su Y; Chen Y; Zhang W Mol Neurobiol; 2017 Jul; 54(5):3264-3270. PubMed ID: 27090900 [TBL] [Abstract][Full Text] [Related]
2. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Wan G; Xiang L; Sun X; Wang X; Li H; Ge W; Cao F Oncotarget; 2017 Jan; 8(3):5382-5391. PubMed ID: 28036271 [TBL] [Abstract][Full Text] [Related]
3. High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma. Zhang W; Chen H; Lv S; Yang H Mol Neurobiol; 2016 May; 53(4):2354-60. PubMed ID: 25983032 [TBL] [Abstract][Full Text] [Related]
4. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231 [TBL] [Abstract][Full Text] [Related]
5. TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells. Pinet S; Bessette B; Vedrenne N; Lacroix A; Richard L; Jauberteau MO; Battu S; Lalloué F Oncotarget; 2016 Aug; 7(31):50349-50364. PubMed ID: 27385098 [TBL] [Abstract][Full Text] [Related]
6. Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas. Huang T; Li S; Yang Z; Liu J; Han Y Mol Neurobiol; 2016 Nov; 53(9):6407-6412. PubMed ID: 26582467 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Bian B; Li L; Yang J; Liu Y; Xie G; Zheng Y; Zeng L; Zeng J; Shen L Cancer Cell Int; 2019; 19():259. PubMed ID: 31624472 [TBL] [Abstract][Full Text] [Related]
8. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594 [TBL] [Abstract][Full Text] [Related]
9. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Thongsom S; Chaocharoen W; Silsirivanit A; Wongkham S; Sripa B; Choe H; Suginta W; Talabnin C Tumour Biol; 2016 Jul; 37(7):9451-63. PubMed ID: 26781979 [TBL] [Abstract][Full Text] [Related]
10. Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis. Tong X; Ma Y; Liu T; Li Z; Liu S; Wu G; Fan H Medicine (Baltimore); 2021 Apr; 100(17):e25631. PubMed ID: 33907118 [TBL] [Abstract][Full Text] [Related]
11. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Tong X; Wang D; Liu S; Ma Y; Li Z; Tian P; Fan H Int J Chron Obstruct Pulmon Dis; 2018; 13():409-418. PubMed ID: 29430175 [TBL] [Abstract][Full Text] [Related]
12. Plasma YKL-40 and CHI3L1 in systemic inflammation and sepsis-experience from two prospective cohorts. Kornblit B; Hellemann D; Munthe-Fog L; Bonde J; Strøm JJ; Madsen HO; Johansen JS; Garred P Immunobiology; 2013 Oct; 218(10):1227-34. PubMed ID: 23706599 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis. Wang J; Qi S; Zhu YB; Ding L World J Clin Cases; 2022 Mar; 10(7):2184-2193. PubMed ID: 35321165 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal/proangiogenic factor YKL-40 related to glioblastomas and its relationship with the subventricular zone. Batista KMP; Eulate-Beramendi SA; Pińa KYÁR; Figueira PR; Canal AF; Chasin JMA; Meilan Á; Ugalde R; Vega IF Folia Neuropathol; 2017; 55(1):14-22. PubMed ID: 28430288 [No Abstract] [Full Text] [Related]
15. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L; Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041 [TBL] [Abstract][Full Text] [Related]
16. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690 [TBL] [Abstract][Full Text] [Related]
17. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature. Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701 [TBL] [Abstract][Full Text] [Related]
18. Analysis of Olig2 and YKL-40 expression: a clinicopathological/immunohistochemical study for the distinction between subventricular zone II and III glioblastomas. Batista K; Costa B; Pablo I; Vega IF; Morales J; Alvarez AV; Meilán A; Astudillo A; Alvarez KY Folia Neuropathol; 2016; 54(1):31-9. PubMed ID: 27179219 [TBL] [Abstract][Full Text] [Related]
19. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816 [TBL] [Abstract][Full Text] [Related]
20. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Nutt CL; Betensky RA; Brower MA; Batchelor TT; Louis DN; Stemmer-Rachamimov AO Clin Cancer Res; 2005 Mar; 11(6):2258-64. PubMed ID: 15788675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]